Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rallybio (RLYB)
NASDAQ:RLYB
RLYB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.73 - $3.46
Previous CloseN/A
Volume36.64K
Average Volume (3M)68.56K
Market Cap
$30.47M
Enterprise Value-$22.73M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Mar 18, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding41,487,587
10 Day Avg. Volume85,113
30 Day Avg. Volume68,557
Standard Deviation0.28
R-Squared0.07
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)50.96
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit151.57
Enterprise Value/Ebitda0.33
Forecast
1Y Price Target
$8.33Price Target Upside981.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Clinical MilestonesThe dosing of the first pregnant subject in the FNAIT study marks a major milestone for Rallybio.
Market PotentialRLYB212 could become the standard-of-care for FNAIT prevention due to the lack of any FDA-approved therapy.
Sales ForecastAnalyst assigns RLYB212 a 60% POS and models peak worldwide sales of >$1.5B, which could be conservative.
Bears Say
Clinical RisksRisks include delays in clinical trials and failure to generate favorable clinical data for key pipeline candidates.
Partnership RisksPartnership risk exists, specifically between Rallybio and companies like Swedish Orphan Biovitrum AB, Exscientia PLC, and Sanofi S.A.
Trial DelaysRisks include delays in clinical trials for pipeline candidates and failure to generate favorable clinical data, particularly for RLYB212 in FNAIT and RLYB116 in PNH.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RLYB FAQ
What was Rallybio’s price range in the past 12 months?
Rallybio lowest stock price was $0.72 and its highest was $3.46 in the past 12 months.
What is Rallybio’s market cap?
Rallybio’s market cap is $30.47M.
When is Rallybio’s upcoming earnings report date?
Rallybio’s upcoming earnings report date is Mar 18, 2025 which is in 26 days.
How were Rallybio’s earnings last quarter?
Rallybio released its earnings results on Nov 07, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.352 by $0.092.
Is Rallybio overvalued?
According to Wall Street analysts Rallybio’s price is currently Undervalued.
Does Rallybio pay dividends?
Rallybio does not currently pay dividends.
What is Rallybio’s EPS estimate?
Rallybio’s EPS estimate is -0.29.
How many shares outstanding does Rallybio have?
Rallybio has 41,487,587 shares outstanding.
What happened to Rallybio’s price movement after its last earnings report?
Rallybio reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.352. Following the earnings report the stock price went down -1%.
Which hedge fund is a major shareholder of Rallybio?
Currently, no hedge funds are holding shares in RLYB
---
Rallybio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.33 (981.82% Upside)
$8.33 (981.82% Upside)
Blogger Sentiment
Bearish
RLYB Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.55%
12-Months-Change
Fundamentals
Return on Equity
-68.90%
Trailing 12-Months
Asset Growth
-40.68%
Trailing 12-Months
Company Description
Rallybio
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
---
RLYB Stock 12 Month Forecast
Average Price Target
$8.33
▲(981.82% Upside)
Technical Analysis
Alnylam Pharma
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering RLYB
1 Year
1 Year Success Rate
1/28 ratings generated profit
1 Year Average Return
-51.20%
reiterated a buy rating 10 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 3.57% of your transactions generating a profit, with an average return of -51.20% per trade.
---